News Sentiment

MRNA sentiment intelligence

Moderna Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 68.27 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-14.4% over one week, +36.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Moderna (MRNA) Stock Looks Stretched On Sales But Reasonable On Momentum

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -14.4% Price reacting lower
Trend fit Trend active 36.8% over four weeks
Fair value 6.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 28
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
simplywall.st 6
TradingView 4
Reuters 3
Stock Titan 3
MarketBeat 2
TIKR.com 2
Bloomberg Law News 1

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 12
Regulatory and legal 3
Analyst action 2
Guidance 2
Capital return 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 46
Reuters Direct company coverage

Sanofi sues Pfizer, Moderna over COVID shot technology

Sanofi has filed lawsuits against Pfizer and Moderna, alleging that their COVID-19 vaccines infringe on multiple patents held by the French pharmaceutical company. The lawsuits claim that the mRNA innovations used in Pfizer and Moderna's blockbuster vaccines violate Sanofi's pate

Tone
Negative 34/100
Event
Regulatory and legal
Published
15 Jul 2026 16:04
Source
Reuters
Bloomberg Law News Direct company coverage

Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties

Sanofi has filed federal lawsuits against Moderna and Pfizer, seeking patent royalties for their COVID-19 and RSV vaccines. Sanofi alleges that Moderna's Spikevax, mNexspike, and mResvia vaccines, and Pfizer's Comirnaty vaccine, infringe upon as many as 10 mRNA delivery patents h

Tone
Negative 38/100
Event
Regulatory and legal
Published
15 Jul 2026 14:59
Source
Bloomberg Law News
Stock Titan Direct company coverage

Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale

Stephen Hoge, a holder of Moderna (NASDAQ: MRNA) stock, has filed a notice for a proposed sale of up to 53,336 common shares. These shares are associated with a stock option exercise dated July 15, 2026, and the sale will be conducted through Fidelity Brokerage Services LLC on th

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 14:39
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies

Jefferies analysts anticipate an uneventful second-quarter earnings report for Moderna, primarily due to the seasonal nature of COVID-19 vaccine sales which are expected to be lower in Q2. The focus for investors remains on Moderna's late-stage pipeline, particularly the upcoming

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 17:38
Source
Yahoo! Finance Canada
TradingView Direct company coverage

MRNY ETF Profile: Dividends, Returns (AMEX:MRNY)

The MRNY ETF, or YieldMax MRNA Option Income Strategy ETF, aims to generate monthly income and provide exposure to Moderna (MRNA) stock's price returns using a synthetic covered call strategy. It does not invest directly in MRNA stocks and therefore does not pass on MRNA dividend

Tone
Neutral 50/100
Event
Capital return
Published
14 Jul 2026 07:44
Source
TradingView
Market source Direct company coverage

Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note

Moderna (MRNA) experienced a 1.89% drop, underperforming the S&P 500, Dow, and Nasdaq, although its shares had previously gained 36.79% year-to-date. The biotechnology company is set to announce its earnings on July 31, 2026, with analysts anticipating a 7.51% EPS growth but a 19

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 21:38
Source
Market source
Trefis Direct company coverage

What It Means To Hold Moderna Stock In A Crash

Moderna (MRNA) stock is highly susceptible to significant, prolonged drops during general market shocks, having experienced an average peak-to-trough decline of 31%—nearly double the S&P 500's average. Despite its current stronger balance sheet and advanced pipeline, the company

Tone
Negative 31/100
Event
Market update
Published
13 Jul 2026 13:06
Source
Trefis
Pharma Voice Direct company coverage

Moderna, Takeda and Capricor on the verge of notching big drug approvals

Moderna, Takeda, and Capricor are anticipating significant drug approvals from the FDA this summer. Moderna is seeking approval for its seasonal flu vaccine, mRNA-1010, after an initial rejection last year. Capricor is making a second attempt for approval of its Duchenne muscular

Tone
Positive 67/100
Event
Regulatory and legal
Published
13 Jul 2026 12:34
Source
Pharma Voice
TradingView Direct company coverage

Weekly Recap: Moderna names Michael McDonnell to board and $950M patent payout

Moderna has appointed Michael McDonnell, former Biogen CFO, to its board of directors and Audit Committee. The company is facing a $950 million patent settlement payment by July 8th, with a potential total payout of $2.25 billion, and has secured an EU deal to supply up to 24 mil

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 11:20
Source
TradingView
MarketBeat Direct company coverage

Y Intercept Hong Kong Ltd Sells 444,343 Shares of Moderna, Inc. $MRNA

Y Intercept Hong Kong Ltd significantly reduced its stake in Moderna, selling 444,343 shares, representing a 96.4% decrease in its holdings. This move comes as Moderna reported a Q1 earnings miss but beat revenue expectations, and recently secured a European Commission RSV vaccin

Tone
Neutral 50/100
Event
Earnings
Published
13 Jul 2026 10:49
Source
MarketBeat